UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (Right to Buy) | Â (1) | 09/10/2025 | Common Stock | 14,084 | $ 28.4 | D | Â |
Stock Option (Right to Buy) | Â (1) | 09/10/2025 | Common Stock | 45,916 | $ 28.4 | D | Â |
Stock Option (Right to Buy) | Â (2) | 02/10/2026 | Common Stock | 969 | $ 9.93 | D | Â |
Stock Option (Right to Buy) | Â (2) | 02/10/2026 | Common Stock | 14,531 | $ 9.93 | D | Â |
Stock Option (Right to Buy) | Â (3) | 10/25/2026 | Common Stock | 25,003 | $ 2.6 | D | Â |
Stock Option (Right to Buy) | Â (3) | 10/25/2026 | Common Stock | 74,997 | $ 2.6 | D | Â |
Stock Option (Right to Buy) | Â (4) | 02/23/2028 | Common Stock | 52,011 | $ 1.52 | D | Â |
Stock Option (Right to Buy) | Â (5) | 02/23/2028 | Common Stock | 18,189 | $ 1.52 | D | Â |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
LUDLAM WILLIAM C/O CHIASMA, INC. 460 TOTTEN POND ROAD SUITE 530 WALTHAM, MA 02451 |
 |  |  See Remarks |  |
/s/ William Ludlam | 04/02/2018 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | This option vests over a four-year period at a rate of twenty-five percent (25%) on August 26, 2016 and 36 equal monthly installments thereafter. |
(2) | This option vests over a four-year period at a rate of twenty-five percent (25%) on February 10, 2017 and in 12 equal quarterly installments thereafter. |
(3) | This option vests over a four-year period at a rate of twenty-five percent (25%) on October 25, 2017 and in 12 equal quarterly installments thereafter. |
(4) | This option vests over a four-year period in 16 equal quarterly installments, the first such installment vesting on May 23, 2018. |
(5) | This option vests as follows: (i) 40% of such award will be earned upon FDA acceptance of a new drug application ("NDA") for Mycapssa, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such acceptance; and (ii) 60% of such award will be earned upon FDA approval of such NDA, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such approval. |
 Remarks: Title: Senior Vice President, Clinical and Medical Affairs |